Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis

NCT: NCT06441266 · ACTIVE_NOT_RECRUITING

NCT IDNCT06441266
StatusACTIVE_NOT_RECRUITING
Start Date2025-05-08
Completion2026-07

Brief Summary

The purpose of this research study is to test the ability of a mobile device application (MyCap) to collect patient information about their radiation skin rash in patients with head and neck cancer being treated with radiation therapy.

Frequently Asked Questions

What is M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis?

M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis is a clinical trial registered under NCT06441266. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06441266?

The current status of NCT06441266 (M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis) is: ACTIVE_NOT_RECRUITING.

When did M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis start?

M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis started on 2025-05-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑